Addex Therapeutics Ltd
ADXN
$7.30
-$0.15-2.01%
| 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | 09/30/2023 | |
|---|---|---|---|---|---|
| Revenue | 62.20K | 127.50K | 267.00K | 173.30K | 371.10K |
| Total Other Revenue | 5.20K | -- | 1.60K | 34.30K | 1.70K |
| Total Revenue | 67.50K | 127.50K | 268.70K | 207.60K | 372.70K |
| Cost of Revenue | 236.40K | 374.10K | 280.40K | 1.75M | 555.60K |
| Gross Profit | -169.00K | -246.60K | -11.70K | -1.54M | -182.80K |
| SG&A Expenses | 550.40K | 747.90K | 889.70K | 1.49M | 665.50K |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 786.80K | 1.12M | 1.17M | 3.24M | 1.22M |
| Operating Income | -719.40K | -994.50K | -901.40K | -3.03M | -848.30K |
| Income Before Tax | -1.77M | -1.61M | -840.80K | -3.23M | -804.70K |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -1.77M | -1.61M | -840.80K | -3.23M | -804.70K |
| Earnings from Discontinued Operations | -2.80K | 15.85M | -2.69M | -- | -2.16M |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -1.77M | 14.24M | -3.53M | -3.23M | -2.96M |
| EBIT | -719.40K | -994.50K | -901.40K | -3.03M | -848.30K |
| EBITDA | -657.40K | -870.20K | -898.00K | -3.02M | -845.00K |
| EPS Basic | -0.02 | 0.14 | -0.04 | -0.04 | -0.04 |
| Normalized Basic EPS | -0.01 | -0.01 | -0.01 | -0.02 | -0.01 |
| EPS Diluted | -0.02 | 0.14 | -0.04 | -0.04 | -0.04 |
| Normalized Diluted EPS | -0.01 | -0.01 | -0.01 | -0.02 | -0.01 |
| Average Basic Shares Outstanding | 98.30M | 98.31M | 97.53M | 86.33M | 77.28M |
| Average Diluted Shares Outstanding | 98.30M | 167.99M | 97.53M | 86.33M | 77.28M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
